



Biweekly Update 25-March 2021

StrokeNet Enrollment Update

ARCADIA	609/1100	TRANSPORT2	30/129
ARCADIA-CSI	150/500	I-ACQUIRE	48/240
Sleep SMART	472/3062	MOST	144/1200
SATURN	75/1456	CREST H	189/500
ASPIRE	21/700	CREST 2	1804/2480

*Enrollment as of 25-March 2021

StrokeNet Trial Updates



FASTEST is excited to continue study start-up! We would like to thank you for your continued efforts and hard work getting FASTEST ready to launch.

Our next webinar will be **Wednesday, April 21st at 2:00 pm ET**. Prior presentations and slides are available -- please contact the FASTEST team for access, as the FASTEST StrokeNet website, <https://www.nihstrokenet.org/fastest/webinars>, is under

maintenance. Thank you for your patience.

The ABC/2 and IVH Score Imaging Training is available, <http://fasteststudy.com>. Team members will need to register for an account, which can take up to 24 hours to activate.

Approved EFIC community-facing template materials, English and Spanish, are available in WebDCU™, in the Toolbox under Project Documents. For the EFIC video, please reach out to the FASTEST team. The EFIC video in Spanish is coming soon! **The updated EFIC forms for local context, community consultation, and public disclosure are now available in WebDCU™. The updated EFIC Resource guide will soon be available in WebDCU™, in the Toolbox under Project Documents. Please reach out to us if you need assistance with EFIC plans or forms.**

FASTEST is excited to announce our partnership with BuildClinical, to support sites with EFIC public disclosure efforts. The NCC will be reaching out to identify a contact person, at each site, to work with BuildClinical and develop a site-specific PD campaign.

A few helpful reminders:

- If you have not submitted an EFIC plan for review, please reach out to the NCC with an update on your site's progress. We would like to hear from sites, even if your site is still developing a plan.
- When you are ready to initiate your EFIC plan, update your DOA log with your EFIC team.
- Reach out if you plan to use the central REDCap survey(s) and need access.

Congratulations to our **24** sites that have submitted EFIC plans to Advarra and are taking next steps to implement them! Since the last update -- **Northwestern Memorial Hospital!**

Upcoming Advarra EFIC Panel meeting dates -- April 12th, 26th, May 10th, 24th and June 14th.

Please contact Pooja Khanolkar (Prime Project Manager), khanolpa@ucmail.uc.edu or Julie Denlinger (NCC Project Manager), denlinjk@ucmail.uc.edu with any questions.

MOST Enrollment Update:

Total randomizations: **144**

Randomizations between 10Mar2021 and 25Mar2021: **8**

Sites released to enroll with at least one subject consented: **39**

There are now **71** sites that have been released to enroll, **58** of which are actively recruiting!

Congratulations to the following sites for randomizing one or more subjects this period! In addition, congratulations to the **Mount Sinai Beth Israel** and **Akron General** teams for **randomizing their first subject**. Thank you for all your hard work on the MOST trial!

- Mount Sinai Beth Israel - Dr. Boniece and Peterson Masigan (**1st subject!**)
- Memorial Hermann Texas Medical Center - Dr. Barreto and Jamey Franklin (**2 new subjects, 15 total subjects!**)
- Yale New Haven Hospital - Dr. Jasne and Sara Jasak (**2 new subjects, 5 total subjects!**)
- University of Cincinnati Medical Center - Dr. Demel and Abby Vollmer (**1 new subject, 11 total subjects!**)
- Barnes Jewish Hospital - Dr. Panagos and James Hermeyer (**1 new subject, 3 total subjects!**)
- Akron General Medical Center - Dr. Gebel and Debbie Hudock (**1st subject!**)

The March **MOST Trial Investigator Call** took place on Monday, 15Mar2021. Thank you to everyone that attended the call. A recording of the webinar, which included MOST Trial Updates, an overview of the MOST Payment for Enhanced Enrollment and tips regarding the Modified Rankin Score Recording at Day 90, can be found at <https://nihstroketnet.adobeconnect.com/pamzp2pv8w2w/>. Please see below a summary of the MOST Payment for Enhanced Enrollment.

- **MOST Payment for Enhanced Enrollment:** As a hyperacute, time-sensitive trial, MOST requires prioritized time and effort from study teams for successful enrollment. The era of COVID has impacted research and pharmacy staffing, and availability of families/legally authorized representatives at the bedside. In acknowledgement of these challenges, MOST will implement the following payment structure for enhanced site enrollment:
 - \$5,000, inclusive of indirect costs, will be paid to the enrolling site if two eligible MOST subjects are randomized within 60 days of each other.
 - The payment eligible window opens on the date of the site's last enrollment if it was within 60 days of 10Mar2021.
 - If there has been no enrollment in the past 60 days, the payment eligible window opens on the day of the site's next enrollment.
 - The payment eligible window closes after 60 days if a second randomization does not occur.
 - If two subjects are randomized within 60 days of each other, a new payment eligible window opens the date that a third subject is randomized.
- The payment will be issued upon study completion for both subjects.
- **This payment is separate from and in addition to the existing per subject monies.**

The next **MOST Investigator Call** will be on **Monday, April 19, 2021 at 2pm ET**. A Zoom invite has been sent to all PIs, Primary Study Coordinators and Secondary Study Coordinators. Please forward the invite to your team's Sub-Investigators, Pharmacists etc. as necessary.

The **updated MOST Enrollment Cards version 3.0** are posted in the Toolbox within WebDCU™. If your site needs additional updated enrollment cards, please email Iris Deeds (irisdeeds@wustl.edu) and updated enrollment cards will be sent to your site.

Please remember to update the email address for **Dr. Opeolu Adeoye** (adeoye@wustl.edu) and **Iris Deeds** (irisdeeds@wustl.edu). Please be sure you are using their respective Washington University in St. Louis email address.

The **PI Hotline** is available 24/7 for any questions: **1-833-229-MOST**.



SATURN has 98 sites open for enrollment and has randomized 75 patients!

SATURN would like to recognize **Dr. Shapshack** and **Tammy Davis** at the **University of Alabama Hospital**, Birmingham for being the top enrolling site with 5 randomizations!

We would also like to recognize both **UPMC** and **Kaiser Permanente LA** for having 4 randomizations!

Keep up the great work!

We want to thank everyone for their efforts to screen recruit and randomize! We ask that sites continue to screen every ICH daily!

IMPORTANT ENROLLMENT REMINDERS

Reminder #1: Sites must confirm the clinician prescribing the statin agrees with trial participation prior to randomizing a patient. This is part of inclusion criteria #5 and should be documented in the patient record. The Provider Information Sheet INITIAL is located in the toolbox on WebDCU and may be used to facilitate this communication. Many top enrolling sites have found it best practice to have the discussion clinician to clinician via telephone. The SATURN statistics for equipoise discussion document may also be found in the toolbox and can be helpful when speaking with the statin prescriber.

Reminder #2: it is important to communicate the subject's randomization assignment to the inpatient clinical team as well as the statin prescriber to ensure the patient will be discharged with the proper medications and instructions. An amended Provider Follow Up Letter has been cIRB approved and may be found in the project toolbox; this updated letter includes a place to note the randomization assignment.

Reminder #3: It is important to review the scan with a Neurologist experienced in neuroimaging or a Radiologist to confirm the lobar location of the ICH. If in doubt, please contact the SATURN team for imaging review before enrolling a subject. This does not need to be done through ASPERA, but can happen in real time via email or text.

SAVE THE DATE: SATURN INVESTIGATOR MEETING (VIRTUAL) will be held April 8th 12:30p-4pm ET
Invitations went out to site PIs and Primary Study Coordinators; we welcome anyone from your site study team who would like to join, you may forward the Zoom invitation.

SATURN is actively looking to add motivated sites; please reach out for further details.

IMPORTANT STAURN CONTACTS:

- **Questions regarding eligibility or protocol implementation**
 - Email: SATURN@bidmc.harvard.edu
- **SATURN Clinical Hotline**
 - Call 617-667-7000 and ask to page beeper #39636.
Please tell the operator that you are calling about the SATURN trial.

Thank you for all your hard work on Sleep SMART! As of March 24, 2021, 1384 subjects have been enrolled and 472 subjects have been randomized.



We are delighted to have the team at **Penn State Hershey Medical Center** formally join Sleep SMART!

NEW SLEEP SMART TOOLS:

1. Scripts -- Our consulting psychologist and widely recognized expert in CPAP adherence, Dr. Mark Aloia, developed scripts for use by study staff in conversations with patients/participants. These scripts are CIRB approved and are intended to help coordinators provide consistent messages to participants across all sites. Please obtain local IRB acknowledgment if required as soon as you can, so that you will be able to start taking advantage of these scripts.
2. Video of conversation with Dr. Aloia about talking to participants -- This video was shown during our March webinar. The video is available on our website, along with bulleted recommendations from Dr. Aloia.


Website link: <https://www.nihstrokenet.org/sleep-smart-trial/research-team>

3. Care management video -- As part of protocol version 7, the new care management video was CIRB approved and should now have been acknowledged by your local IRB, if required. Please remember to show this to all intervention subjects prior to discharge. The timing of this is outlined in the scripts mentioned above. This video explains the supportive role of FusionHealth to subjects and caregivers. Website link: <https://www.nihstrokenet.org/sleep-smart-trial/patients>

MOP VERSION 5.0:

The new version of the MOP allows for the 3 month visit to be completed earlier. The new window for the 3-month visit is now – 30 days to + 30 days. Please review the email that was sent to all sites by Kayla on Monday, 3/22/2021.

IMPORTANT INFORMATION TO REMEMBER:

A grey speech bubble with a black outline, pointing downwards.

Eligibility Questions?
sleepsmart@umich.edu

The 3-month mRS is a primary outcome for Sleep SMART. Please complete all 3-month assessments within window, which has now been expanded. The target is still 90 days from randomization, but the window now runs from -30 days to +30 days. The earlier start for this window is designed to take better advantage of any opportunities for overlap with post-hospitalization follow-up visits scheduled for clinical purposes. However, the outcome assessments can be done by phone, if necessary, and should be completed by a blinded assessor if possible.

Corrective Action Plan (CAP): After one additional out of window or missed 3-month or 6-month visit, a CAP will need to be completed by your site. If an additional visit is missed while a CAP is ongoing, site probation

will be triggered. Please try your best to obtain these critical outcome assessments.

End of Study (EOS): If you have a subject who moved to EOS, please document in WebDCU™ as soon as possible. Completing this CRF lets FusionHealth know the subject has completed participation. If not completed, you will likely receive emails from NDMC, Kayla, and the FusionHealth team asking about the subject's status.

A “warm transition” for intervention (CPAP) subjects should be completed sometime prior to discharge. This contact between intervention subjects and the FusionHealth Care Team helps facilitate CPAP adherence post-discharge.

SAVE THE DATES:

PI/Coordinator webinar April 12, 2021 1-2 ET

Virtual Investigator/Coordinator Meeting June 7, 2021 1-4 ET. Please save the date!



ARCADIA•CSI
Cognition & Silent Infarcts

Site Startup and Enrollment Updates

Sites: 73/108 Subject Enrollment: 149/500

Welcome to the new sites who have agreed to join CSI: **Central DuPage**
Swedish Medical Center-Cherry Hill

Important Updates:

MOP

The manual of procedures (MOP) is almost complete and will be added to WebDCU™ when complete

eConsent:

Please complete and return the Remote Implementation form for your site, if you haven't done so already. This form lets us know if your site will need an eConsent database in RedCAP.

DCRs and Form 515:

We have several sites that have enrolled subjects into CSI but have not completed Form 515. The form is found in the ARCADIA database and must be completed within a few days of enrollment into the study. If the subject declines, you will still need to complete the form.

Please review the queries from the monitors and answer all of them in a timely fashion, many are from over a year ago. If you need any assistance, please reach out to study staff.

Please contact Tashia Harris, herndotl@ucmail.uc.edu or Stephanie Kemp, skemp@stanford.edu with any questions.



ARCADIA: Picking Up Steam! We Passed 600 Patients!

ARCADIA

Sites worked hard this month to increase the number of randomizations. We are currently at 22 for March! We're grateful for your commitment to ARCADIA!

Thanks in particular to the **McLaren Macomb, Mount Clemens, MI** team for bringing us to the 600th randomization in ARCADIA and to the team at **Hospital of the University of Pennsylvania, Philadelphia, PA** for randomizing two subjects in this period!

ARCADIA randomized a total of 609 participants since the study started, an increase of 12 in two weeks at eleven sites. Remember that we still have a pool of 39 subjects eligible and pending randomization --please continue to conduct randomization visits safely and as per protocol. A special thanks to the eleven teams that provided the last randomizations during this period: Grady Memorial Hospital, Atlanta, GA; Mayo Clinic, Jacksonville, FL; Mercy Health Saint Mary's, Grand Rapids, MI; Methodist University Hospital, Memphis, TN; Northwestern Memorial Hospital, Chicago, IL; NYP Weill Cornell Medical Center, New York, NY; NYU Langone Medical Center - Tisch Hospital, New York, NY; University of Alabama Hospital, Birmingham, AL and University of Chicago Medical Center, Chicago, IL.

We are currently at 2,313 subjects consented for biomarker assessment, an increase of 30 in less than 2 weeks, thanks to 27 sites. This also means we have sites that have enrolled multiple subjects over the past 2 weeks - thank you to all the teams making each enrollment possible! A special thanks to the teams at Rancho Los Amigos National Rehabilitation Center, Downey, CA; Rhode Island Hospital, Providence, RI and Salinas Valley Memorial Hospital, Salinas, CA for enrolling more than one subject and to Cooper University Hospital, Camden, NJ for enrolling their first subject since being released to enroll in December!

Reminders & Clarifications for Coordinators

We are asking that all subject data is up-to-date in WebDCU™ by April 15, 2021 for the upcoming database transfer for the DSMB meeting. Please address any outstanding data, unresolved DCRs, and open rule violations in WebDCU™ prior to the scheduled database transfer. Please note that you will still be able to access WebDCU™ during the transfer, however we need to ensure the data is as up-to-date as possible.

Please don't hesitate to reach out to the Data Managers if you have any questions (Faria Khattak khattak@musc.edu or Patty Hutto huttoja@musc.edu).

Save yourselves some time and make sure you only enter ESUS patients on your **monthly screening logs** that have not met our inclusion/exclusion criteria or have refused the trial.

Continue to let us know if you know of a good site that would like to participate in ARCADIA.

We still have six sites pending re-start after the COVID pause. We understand some of the sites cannot yet re-start, but when ready, please reach out to Rebeca (ra2356@cumc.columbia.edu) to review any pending items needed for your re-release. PLEASE do not start enrolling new subjects until your site has been officially re-released to enroll.

Webinar: Our next PI and coordinator webinar will be April 27th at 2 PM Eastern--save the date! We're requiring at least 1 person from each site attend the monthly webinar and pass the information along to their team. Also, please send suggestions for topics you'd like discussed.



From the CREST-2 Clinical Coordinating Center:

1804 Overall

953 CEA

851 CAS



We've reached 1800! Congratulations to UPMC Presbyterian who randomized the 1800th (and 1700th 😊) CREST-2 patient! Pictured to the left is Nancy Tran (Sonographer), Dr. Matthew Starr (Principal Investigator), and Jason Weimer (Coordinator).

We are currently at 13 randomizations for the month of March – 5 more working days to surpass last month of 17! Congratulations to the following StrokeNet sites that have randomized since the last update: **UPMC Presbyterian, University of Alabama at Birmingham, and VA Ann Arbor**. Special recognition to the VA Ann Arbor who randomized back-to-back patients!



Overall Enrollment Summary: sites: **56**; Total Enrollments: **189/350 (54% of target)**


Number of enrollments in March = 6

We would like to thank **Vancouver, UPMC, UAB, Novant, Utah, and Tennova** for enrolling in March. For Tennova, it was their first!

We greatly appreciate your efforts, especially during these difficult times! Please keep up the good work and feel free to contact us if you need any assistance along the way.

We are keeping up with our enrollment targets, nearly back to our pre-COVID rates. **Keep an eye out for the new CREST-H video.** This 3-minute, patient-oriented information video we hope will help with enrollment.

Interested in becoming a CREST- site? Contact Randy Marshall 212-305-8389 or Kevin Slane 212-342-1152 at Columbia, or Ron Lazar 205-935-2234 at UAB with any questions.





Congratulations to the Baltimore Site for randomizing their first participant!

We now have **48** study participants enrolled. Everyone's hard work is greatly appreciated!

- Ann Arbor, MI – **6** participants randomized (**1** in the past 90 days)
- Baltimore, MD- **1** participant randomized (**1** in the past 90 days)
- Boston, MA – **15** participants randomized (**3** in the past 90 days)
- Cincinnati, OH – **4** participants randomized (**1** in the past 90 days)
- Columbus, OH – **5** participants randomized (**1** in the past 90 days)
- Chicago, IL– **2** participants randomized
- La Jolla, CA – **5** participants randomized
- New Haven, CT – **3** participants randomized
- Philadelphia, PA – **2** participants randomized (**1** in the past 90 days)
- Roanoke, VA – **5** participants randomized (**1** in the past 90 days)

Save the dates: Upcoming **2021** PI/Co-I/Coordinator Webinar:

Thursday 22 April (12-1pm ET)
Thursday 13 May (12-1pm ET)
Thursday 10 June (12-1pm ET)



Our next PI and Coordinator call will be on **Monday, 4/05/2021 at 11am ET**. If anyone has topics they would like to discuss during the call, please send them to Kristina Balderson (Kristina.balderson@duke.edu).

13 sites have reopened to enrollment! Congratulations to MUSC, Burke, Baystate, Medstar, UAB, USC, Kentucky, Houston, Cincinnati, Moss, Emory, UPMC, and Duke for being open to enrollment amidst the COVID-19 restrictions.

There are 30 subjects randomized in the trial, 19 have completed the study and we have several subjects we are hoping to randomize this month.

- UK, Lexington, KY- **2** participants randomized (**1** in the past 90 days)
- Duke, Durham, NC- **6** participants randomized (**2** in the past 90 days)
- Emory, Atlanta, GA- **3** participants randomized (**1** in the past 90 days)
- USC, Los Angeles, CA- **1** participant randomized
- MedStar, Washington, DC- **5** participants randomized (**1** in the past 90 days)
- Moss, Elkins Park, PA- **4** participants randomized (**1** in the past 90 days)
- UAB, Birmingham, AL- **3** participants randomized (**2** in the past 90 days)
- UC, Cincinnati, OH- **6** participants randomized (**1** in the past 90 days)

-TRANSPORT2 Team



ASPIRE

Anticoagulation in Intracerebral Hemorrhage Survivors for Stroke Prevention and Recovery


ENROLLMENT:

21 Subjects have been randomized in ASPIRE. 6 more have been consented and are pending randomization!

Congratulations to **Jennifer Fontera, MD** and **Maria Cotrina-Vidal, PhD** from **NYU Langone Hospital – Brooklyn, NY** for randomizing their first subject!

The following sites also randomizes subjects this week:

- University of Alabama Hospital – PI: Angela Shapshak, MD Coordinator: Tammy Davis
- Prisma Health - Greenville Hospital System – PI: Sanjeev Sivakumar, MD Coordinator: Sam Thavarajah



STUDY NEWS:

New guidelines and materials have been posted to the ASPIRE Toolbox in WebDCU:

- **How to Be a Successful ASPIRE Site:** *Tips and advice for screening, consenting, enrolling and follow-up.*
- **ASPIRE Guidance on Partnering with Rehabilitation or Skilled Nursing Facility:** *Recommended procedures to follow if a consented/enrolled patient enters a rehab/SNF to facilitate initiation/continuation of study drug and scheduled contacts.*
- **StrokeNet Rehab-SNF Letter ASPIRE:** *Letter signed by StrokeNet leadership to share with facilities as needed.*
- **How to Talk with PCP-Cardiologists about ASPIRE:** *Advice on discussing study issues (equipoise, LAA closure) with HCPs.*

SITE CHECK-IN CALLS:

We will be contacting sites to schedule check-in calls in the next few weeks. The goal of these calls is to receive feedback regarding the study and to learn about what your experience with the protocol.

INVESTIGATOR WEBINAR:

An online **Investigator Meeting** is being planned for **May 5, 2021 from 2:00p-4:00p EDT**. We hope at least 2 people from each site will be able to attend (preferably, the PI and primary study coordinator).

STUDY NETWORK:

98 sites have been released to enroll and **33 sites** are pending activation.

ASPIRE is looking to add new motivated sites. Please contact ASPIRE@yale.edu if your site would like more information about participating in the ASPIRE Trial.

Our next Webinar is April 28, 2021 3:00p-4:00p EDT.



The inpatient ACTIV-4A platform is now focused on determining the optimal antiplatelet strategy (on top of the optimal anticoagulation strategy determined by the study for each sub-cohort).

As of March 25, 2021, ACTIV-4A had randomized 97 subjects (31 severely ill and 66 moderately ill patients) in the antiplatelet arms nationally.

CONGRATULATIONS to following StrokeNet sites who are now open to enrollment:

1. **Kaiser Permanente Fontana, Dr. Conrad Liang**
2. **Kaiser Permanente Los Angeles, Dr. Zahra Ajani**
3. **SUNY Upstate Medical Hospital, Dr. Julius Lattore**
4. **Mercy Hospital Buffalo, Dr. Raed Aljani**

Six additional sites are in startup, including five sites pending subaward approval and 3 sites pending IRB approval.

StrokeNet is still **actively seeking additional motivated sites** to participate in ACTIV-4A. Please contact Amy Sulken, StrokeNet NCC Project Manager, sulkenay@ucmail.uc.edu, Pooja Khatri, MD khatrip@ucmail.uc.edu, Hooman Kamel, MD hok9010@med.cornell.edu or Jamey Frasure frasurej@ucmail.uc.edu for more information.

Reminder: The first Wednesday of every month at 1pm EDT is a Study-Wide Webinar to update all sites across ACTIV-4A. Mark your calendar for the next one on April 7th.



As of March 25, 2021, the post-hospital ACTIV-4C platform had randomized 8 subjects.

CONGRATULATIONS to the following **6 StrokeNet sites** participating in ACTIV-4A that have agreed to participate in ACTIV-4C as well.

1. **Kaiser Permanente Fontana**
2. **Kaiser Permanente Los Angeles**
3. **Queens Medical Center**
4. **Mercy Hospital Buffalo**
5. **St. Mary's Hospital and Medical Center**
6. **Swedish Medical Center**

These six sites are just beginning the startup process.

StrokeNet is **actively seeking additional motivated sites** to participate in ACTIV-4C. Please contact Amy Sulken, StrokeNet NCC Project Manager, sulkenay@ucmail.uc.edu, Pooja Khatri, MD khatrip@ucmail.uc.edu, Hooman Kamel, MD hok9010@med.cornell.edu or Jamey Frasure frasurej@ucmail.uc.edu for more information.

Feasibility Survey Reminder

The **ADIOSS Feasibility Survey** has been sent to RCCs for review and completion. This is an ancillary study to SleepSMART.

Surveys MUST be completed in WebDCU™ by 11:59pm ET on Monday March 29th.

NIH News

The Impact of the COVID-19 Pandemic on the Extramural Scientific Workforce – Outcomes from an NIH-Led Survey

Please visit <https://nexus.od.nih.gov/all/2021/03/25/the-impact-of-the-covid-19-pandemic-on-the-extramural-scientific-workforce-outcomes-from-an-nih-led-survey/> to review the very interesting findings from this survey.

Top Three Applicant and Grantee Systems Resources

To help people navigate NIH grant systems, the eRA website provides a myriad of resources. Below are three that you may find very helpful:

1. eRA Commons Online Help – Step by step instructions
<https://era.nih.gov/erahelp/Commons/default.htm>
2. eRA Video Tutorials – Quick overviews
<https://era.nih.gov/era-training/era-videos.htm>
3. eRA Commons FAQs – For helpful answers
<https://era.nih.gov/faqs.htm>

Also, don't hesitate to contact the eRA Service Desk at <https://grants.nih.gov/support/index.html> or email grantsinfo@od.nih.gov.

NIH StrokeNet Coordinator Webinar

Coordinator Webinars are a requirement for the NIH StrokeNet RCC Coordinators/Managers however, all are welcome to attend

**Wednesday, April 28, 2021
1:30 pm ET**

Topics: RPPR Updates and Information
Joanna Vivalda, NINDS
RCC Structures
Diane Sparks, NCC Contracts Manager

Moderator: David Haney, RT, Case Western Reserve University

To join the meeting: <https://nihstrokenet.adobeconnect.com/coordinator/> Please enter as a guest, then your email address or your first and last name. To take part in the conversation you MUST dial in. (877) 621-0220; Passcode: 434578

Steering Committee Call

Steering Committee Calls are a requirement for all NIH StrokeNet RCCs; Please invite satellite sites to attend

The NIH StrokeNet Spring Network Webinar is scheduled for **Wednesday, 14-April, 2021, from 12 noon – 3:00 pm ET.** An agenda will follow soon.

Professional Development Webinar

Professional Development Webinars are a requirement for the NIH StrokeNet Trainees
The next PDW is TBD. We will keep you posted.

Grand Rounds

Grand Rounds are a requirement for the NIH StrokeNet Trainees, however all are welcome to participate.
Thursday, April 29, 2021
4:00 pm ET

Topic: Cell Based Regeneration Therapies for Stroke

Presenters: Sean Savitz, MD, University of Texas at Houston

Moderator: Randy Marshall, MD

To join the meeting: <https://nihstrokenet.adobeconnect.com/grandrounds/>. Please enter as a guest, then your email address or your first and last name. To take part in the conversation you MUST dial-in. (877) 621-0220
Passcode: 190825

NIH StrokeNet Employment Opportunities

Medical University of South Carolina - Stroke Faculty Position in Charleston, SC

The Medical University of South Carolina (MUSC) Department of Neurology is recruiting a Vascular Neurologist as part of further expansion of our pre-eminent Comprehensive Stroke Program. The successful applicant must be board-eligible or board certified in general neurology and have completed ACGME-fellowship training in Vascular Neurology.

MUSC is one of the busiest stroke programs in the Southeast and is the tertiary referral center for most large artery strokes in the state. MUSC is a leader in the South Carolina Telestroke Alliance and currently provides acute stroke care to 30+ SC hospitals and admits over 1200 stroke patients annually. MUSC also has a robust clinical research enterprise and is a national leader in investigator-initiated research and clinical trials, including serving as a regional coordinating center in the NIH-funded StrokeNet.

The chosen candidate for this position will be appointed as an Assistant Professor (or higher commensurate with experience) on the Clinician Educator Track. He/she will participate in the clinical activities within the MUSC Stroke Program including rounding on the Inpatient Stroke Teaching Ward Service, the Stroke Consult Service, Outpatient Stroke Clinic, and the Telestroke consult program. Exposure and familiarity with tele-stroke and tele-neurology consultations and services is suggested. Excellent communication skills, ability to work collaboratively in an interdisciplinary setting, and experience teaching vascular neurology fellows, house-staff and medical students, as well as experience with clinical trials are desired. *Position available starting July 2021.*

For more information, please contact Dr. Tanya Turan, Stroke Division Director at turan@musc.edu or 843-792-3020.

*For more information about StrokeNet employment opportunities, please visit
<http://nihstrokenet.org/education/employment-opportunities>*

Contact: Jamey Frasure, PhD, RN, Administrative Director · frasurjs@ucmail.uc.edu <https://www.nihstrokenet.org>